Day: January 5, 2023

TORONTO, Jan. 05, 2023 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has granted the Company’s Type C meeting request to obtain agreement on the revised protocol endpoints for the Company’s Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. The goal date for the FDA to provide its written responses is March 7, 2023. The Company is not making any express or implied claims that its product has the ability to eliminate...

– Determination of Recommended Phase 2 Dose and Start of Phase 2 in 1Q 2023 for Oral Fadraciclib – – 2/3 Partial Responses in Lymphoma and 11/15 Stable Disease in Advanced Solid Tumors – – Expecting Key Data Readouts for Oral Fadraciclib in 2023 – – Expecting Preliminary Safety and Efficacy Update for Oral Plogosertib (formerly CYC140) in Advanced Solid Tumors in 1H 2023 – – Existing Cash Until End of 2023 Support Multiple Data Readouts – BERKELEY HEIGHTS, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today provided a business update reviewing 2022 achievements and outlining the Company’s key business objectives for 2023. “2022 was a...

Five new products are designed to meet the expanding needs of EV markets across the globe, giving EV drivers more access, more options and greater flexibility Las Vegas, NV, Jan. 05, 2023 (GLOBE NEWSWIRE) — Blink Charging Co. (NASDAQ: BLNK, BLNKW) (“Blink” or the “Company”), a leading manufacturer, owner, operator and provider of electric vehicle (EV) charging equipment and services, today launched five new products at the Consumer Electronics Show (CES) 2023. The new products include the Vision, EQ 200, Series 3, PQ 150, and 30kW DC Fast Charger, which are designed to serve the increasing demands of the growing EV markets across the U.S., Europe, Asia and Latin America. Blink Charging will be showcasing the new products, along with their broader line of EV charging solutions, at the Las Vegas Convention Center’s West Hall at booth...

UNIONDALE, N.Y., Jan. 05, 2023 (GLOBE NEWSWIRE) — Flushing Financial Corporation (the “Company”) (Nasdaq: FFIC), the holding company for Flushing Bank (the “Bank”), announced today that Michael J. Russo, a Board Member, has retired effective January 4, 2023. Michael J. Russo, served as a Director on the Board of the Company and the Bank. He was a member of the Board of Directors of the Company since its formation in 1994 and of the Bank since 1984. Michael J. Russo is self-employed as a consulting engineer and serves as Chief Executive Officer and Corporate Secretary of Fresh Meadow Mechanical Corp., a mechanical contracting firm. Mr. Russo is also President and Director of Operations of Northeastern Aviation Corp., an aircraft charter and management firm, and is a partner in AMF Associates, a commercial real estate company. Mr....

– Patent covers methods of treating cancer with an IL-2 Superkine and PD1/PDL1 or CTLA-4 checkpoint inhibitor, administered in combination or as a single agent BiSKIT™ TORONTO and HOUSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,542,312 titled “IL-2 Superagonists in Combination with Anti-PD-1.” The patent provides intellectual property (IP) protection for methods of treating cancer with an IL-2 Superkine such as MDNA11 and a PD1 (for example, pembrolizumab), PDL1 or CTLA-4 checkpoint inhibitor in combination, as planned in the on-going ABILITY clinical trial, or as a single agent using our BiSKIT™...

WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 2:15 PM PST. A live webcast of the presentation will be available on the Investor section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference. About Morphic TherapeuticMorphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic...

Digital financial services leader expands geographic footprint and bolsters complementary remittance product platform SEATTLE and TEL AVIV, Israel, Jan. 05, 2023 (GLOBE NEWSWIRE) — Remitly Global, Inc. (NASDAQ: RELY) (“Remitly”), a leading digital financial services provider for immigrants and their families in over 170 countries around the world, today announced the successful completion of its previously announced acquisition of Rewire, an Israeli-based remittance and financial services platform for migrant workers, on January 5, 2023. “Today marks an exciting milestone as we enter a new phase of Remitly’s journey,” said Matt Oppenheimer, Co-Founder and CEO, Remitly. “We are thrilled for the Rewire team to join Remitly, bringing with them a strong account based remittance product in complementary geographies and a track record...

New Company-Owned Retail Locations to Bring Total Global Count to 14 BREA, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) — Reborn Coffee, Inc. (NASDAQ: REBN) (“Reborn”, or the “Company”), a California-based retailer of specialty coffee, today announced plans to open new company-owned retail locations in Southern California and Korea, which, once opened, will bring its total global footprint to 14 stores. Reborn’s new store in Pasadena will be located in the area formerly known as the Playhouse District, home to the renowned Pasadena Playhouse along with museums, galleries, eateries, and independent shops. The area is surrounded by the Fuller Theological Seminary, Pasadena City College and CalTech University that serve a combined 30,000+ students, faculty and staff. A second new Southern California store is located in Irvine, a city...